LOS ANGELES, Apr 11, 2006 (BUSINESS WIRE) -- Health Sciences Group, Inc. (HESG) , provider of innovative nutraceutical products and functional food ingredients derived from natural sources, today announced the introduction of Sequesterol(TM) Advanced Cardio Formula. In advance of its national debut in an infomercial slated to air during the second quarter, Sequesterol(TM) is now available for purchase on-line at www.sequesterol.com.
Sequesterol(TM) contains a proprietary blend of clinically-studied ingredients selected by a leading medical professional and formulated to take a multi-faceted approach to maintain and support ones coronary vascular system. This combination includes: cassia nomame, octacosanol, and omega-3 fatty acids. Sequesterol(TM) combines the benefits of these powerful nutrients with heart-healthy vitamins.
A comprehensive website for Sequesterol(TM) is expected to go on-line in May followed by airing of the infomercial, expected in June.
Notice: Sequesterol(TM) is a nutritional supplement that is not intended to diagnose, treat, cure or prevent any disease. The statements made about Sequesterol(TM) in this press release have not been evaluated by the Food and Drug Administration.
About Health Sciences Group, Inc.
Health Sciences Group identifies, develops and commercializes innovative nutraceutical products derived from natural sources to provide consumers and medical professionals with preventative healthcare alternatives. The company markets its own line of proprietary products based on novel technologies with clinically-supported, GRAS-certified ingredients. For more information, visit www.HSciences.com and www.Sequesterol.com.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, the independent authority of the special committee to act on the matters discussed, the successful negotiation of the potential acquisition and disposal of transactions described above, successful implementation of the company's business strategy and competition, any of which may cause actual results to differ materially from those described in the statements. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission.